Formamide

Formamide

SCHEMBL5117411

NC=O.O=C(NCc1ccc(Cl)cc1)C1=NOC2(CCN(c3ccc(C(F)(F)F)cc3)CC2)C1

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
CA7 P43166 3/20 0.41
CA9 Q16790 3/20 0.41
AKT2 P31751 1/20 0.39
HDAC1 Q13547 1/20 0.38
TP53 P04637 1/20 0.38
MDM2 Q00987 1/20 0.38
MAPT P10636 1/20 0.38
ACE2 Q9BYF1 1/20 0.38
PTGER4 P35408 1/20 0.38
CYP3A4 P08684 3/20 0.37
CYP2C9 P11712 2/20 0.37
ADORA1 P30542 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formamide SCHEMBL5126916 0.94 SMN1; SMN2 (0.44) HTTSMN1; SMN2NPSR1CA1CA2
Formamide SCHEMBL5118917 0.87 SMN1; SMN2 (0.43) HTTSMN1; SMN2NPSR1CNR1CNR2
Formamide SCHEMBL5126269 0.85 NPC1 (0.44) SMN1; SMN2MAPT
Formamide SCHEMBL5120208 0.84 DUSP3 (0.41) CA1CA2CA7CA9
Formamide SCHEMBL5120507 0.83 NPC1 (0.39) CA1CA2CA7CA9MAPT
SCHEMBL1456961 0.83 EPHX2 (0.51)
Formamide SCHEMBL5115801 0.78 CXCR3 (0.47)
SCHEMBL5126307 0.78 MAPT (0.41) HTTNPSR1TP53MDM2MAPT
SCHEMBL1457242 0.78 HRH3 (0.45) HTTSMN1; SMN2MAPT
SCHEMBL12825219 0.77 TACR1 (0.43) SMN1; SMN2HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080214807-A1 Substituted Spiro Compounds and their Use for Producing Drugs GRUENENTHAL GMBH (DE) 2008-09-04 US claimed
US-20080214807-A1 Substituted Spiro Compounds and their Use for Producing Drugs GRUENENTHAL GMBH (DE) 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214807-A1 Substituted Spiro Compounds and their Use for Producing Drugs REN, PKD1, NR3C2 HTT 1428/4885SMN1; SMN2 4677/4885NPSR1 438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.